Joshi SK, Huang A, Pittsenbarger J, Shinde U, Posso C, Piehowski PD, Gosline SJ, Press RD, Gritsenko MA, Hutchinson C, Weitz KK, Watanabe-Smith K, Long N, Rodland KD, Tyner JW, Druker BJ, Tognon CE. Oncogenic <i>NTRK3</i> mutations exhibit differential sensitivity to tropomyosin receptor kinase inhibitors in patients with acute myeloid leukemia. haematol [Internet]. 2020Sep.10 [cited 2025Mar.6];. Available from: https://haematologica.org/article/view/11940